secwatch.observer — SEC 8-K summary
======================================

Issuer:     Benitec Biopharma Inc. (BNTC)
CIK:        0001808898
Form:       8-K
Filed at:   2024-07-01T23:59:59+00:00
Accession:  0001193125-24-173338
Event type: leadership
Sentiment:  positive
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Benitec appoints Kishen Mehta to board; Suvretta Capital portfolio manager
--------------------------------------------------------------------------

- Appointed as Class I director effective June 26, 2024, term through 2026 annual meeting.
- Mehta is portfolio manager at Suvretta Capital, which led $40M PIPE financing in April 2024.
- Will serve on Nominating and Corporate Governance Committee; board deemed him independent.
- Also serves on Biohaven Pharmaceuticals board; 15+ years healthcare investing experience.
- Appointment follows Board Designation Agreement with Suvretta disclosed in prior 8-K.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1808898/000119312524173338/0001193125-24-173338-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1808898/000119312524173338/d853226d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-173338

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer